GlassScriptPhysician profile
Jamie Ronzoni
NPI 1447760699
$1,653.99
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $510 · 2023: $145 · 2024: $201 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $253.66 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.07 | 2021-2022 | |
| Amgen INC. | $161.20 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.73 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $137.32 | 2022-2024 | Farxiga, Brilinta |
| Pfizer INC. | $108.51 | 2022-2025 | |
| Edwards Lifesciences Corporation | $70.29 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.33 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.14 | 2021-2022 | |
| Abbott Laboratories | $48.41 | 2021-2025 | Cardiomems |
| Advanced Oxygen Therapy INC. | $40.68 | 2025 | Topical Oxygen Chamber For Extremities |
| Kiniksa Pharmaceuticals, LTD. | $40.13 | 2021 | |
| Ibsa Pharma INC. | $36.56 | 2021 | |
| Bardy Diagnostics, INC. | $36.24 | 2022 | |
| Irhythm Technologies, INC. | $32.38 | 2023 | Zio Xt Patch |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.19 | 2021 | |
| Boston Scientific Corporation | $23.69 | 2022 | |
| Akcea Therapeutics, INC. | $23.55 | 2021 | |
| Axonics, INC. | $21.55 | 2023 | Axonics, Bulkamid |
| Takeda Pharmaceuticals U.S.A., INC. | $21.16 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.75 | 2022 | |
| Mannkind Corporation | $18.23 | 2022 | |
| Medicomp INC | $14.35 | 2022 | |
| Merck Sharp & Dohme LLC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Ronzoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.